Blackwood, Catherine B. http://orcid.org/0000-0002-5898-6736
Mateu-BorrĂ¡s, Margalida
Sen-Kilic, Emel http://orcid.org/0000-0003-1583-2056
Pyles, Gage M.
Miller, Sarah Jo
Weaver, Kelly L. http://orcid.org/0000-0002-6954-2479
Witt, William T.
Huckaby, Annalisa B.
Kang, Jason http://orcid.org/0000-0001-5736-0005
Chandler, Courtney E.
Ernst, Robert K. http://orcid.org/0000-0001-5016-8694
Heath Damron, F. http://orcid.org/0000-0002-3140-402X
Barbier, Mariette http://orcid.org/0000-0002-3250-3636
Funding for this research was provided by:
Cystic Fibrosis Foundation (BARBIE18G0)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (1R01AI14167101A1, 5R01AI13715503)
West Virginia University (WVU) Vaccine Development Center WVU institutional startup support
West Virginia Space Grant Consortium
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32 GM133369)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases
Division of Science and Research, WV Higher Education Policy Commission
Article History
Received: 22 December 2021
Accepted: 17 October 2022
First Online: 10 November 2022
Competing interests
: M.B., F.H.D., and C.B.B. have submitted a provisional patent application (US Patent Application Serial No. 63/172,259, Cross-protective antigens for vaccination, WVU reference number 2021-035) for the work described in this publication. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.